University of Lethbridge researching possible Parkinson’s disease treatments

The University of Lethbridge has been chosen to research GB Sciences' new patent-protected formulations of a potential Parkinson’s disease (PD) treatment.
Led by Dr. Robert Sutherland, the study will focus on the cannabis-based formulations as a way to potentially slow down or possibly reverse the symptoms of PD.
One cause of PD is the death of nerve cells in the basal ganglia. This area of the brain controls bodily movement, and the cells that die are dopamine-producing cells. The lack of dopamine produced by the basal ganglia results in some of the common symptoms, like shakiness, difficulty with coordination and balance issues.
Another cause is the death of nerve endings that produce norepinephrine, the main chemical messenger of the nervous system. This results in other symptoms, like fatigue, irregular blood pressure, and decreased movement of food through the digestive tract.
Sutherland says the causes of PD make it difficult to treat, but he is hoping this study will be a breakthrough in potential treatments.
"Right now there’s no cure for Parkinson’s disease, there’s no treatment that even slows down the process significantly and that’s an important fact," Sutherland said.
"It’s the second most common neurodegenerative disorder after Alzheimer’s disease. So finding anything that produces a benefit or could actually pause the disease progression is really significant."
The cannabis-based formulations don’t have any THC or other psychoactive chemicals in them. Rather than trying to mimic dopamine, it hopes to protect the dopamine producing cells.
"There is no direct dopamine effect, so these cannabinoids do not mimic dopamine, but they do tend to have a neuroprotectant function. So there’s an endogenous process inside the brain of people with Parkinson’s Disease that slowly kills off the dopamine neurons and it’s thought that these mixtures will actually block or interfere with that killing off of the dopamine neurons," Sutherland says.
While the formulation is expected to protect these neurons, it’s possible that it could even help dying cells recover.
"There’s a little bit of residual capacity in these dopamine neurons to recover from damage, and a second possible mechanism of action is that these compounds actually stimulate recovery of dopamine neurons. So as well as being protective, they may actually increase the health of dopamine neurons that are remaining," Sutherland says.
Dopamine and norepinephrine neurons share many similarities, so it’s possible that the formulations could impact both leading causes of PD.
"There’s a lot of similarities between dopamine neurons and norepinephrine neurons neurochemically. They resemble each other. So there’s a good possibility that this would be neuroprotective or reverse the symptoms of norepinephrine loss as well," Sutherland says.
Ultimately, the main goal of the study is to put the brakes on PD progression, and to reverse some of the symptoms.
"The main point is to make sure we can reverse these symptoms. So can we actually restore normal movement functions? That’s goal number one," Sutherland says.
The study began last week, and is divided into three steps:
- Test the correct dosage range of the formulation with normal mice. This is a dose-response experiment where they apply three different doses to mice and continuously monitor their behavior under the influence of the formulation. This is to make sure there aren’t any serious side effects.
- After finding the correct dosage, apply it to mice that have a form of experimental PD. This is to see if it improves their movement, and whether or not the mixtures in the appropriate dose can restore some function.
- Testing if the formulation can block the death of dopamine neurons in mice. On top of that, they will also see if it’s possible to reverse symptoms.
Currently, the study is in the early stages of the first steps.
CTVNews.ca Top Stories
Deceased found in St. Lawrence River were trying to cross U.S. border: police
The six people whose bodies were recovered from the St. Lawrence River Thursday consisted of two families of Romanian and Indian origins who were likely trying to enter the U.S. illegally, police said Friday.

Ottawa gives final approval for Rogers $26B purchase of Shaw
Rogers Communications Inc's $26-billion takeover of Shaw Communications Inc. cleared the last regulatory hurdle Friday, more than two years after the deal was first announced.
Donald Trump indicted; 1st ex-president charged with crime
Donald Trump has been indicted by a Manhattan grand jury, prosecutors and defense lawyers said Thursday, making him the first former U.S. president to face a criminal charge and jolting his bid to retake the White House next year.
These are the conditions -- and penalties if violated -- of the Rogers-Shaw deal
Canadian Industry Minister François-Philippe Champagne has approved Rogers Communications Inc.'s $26-billion takeover of rival telecom Shaw Communications Inc., but there are conditions attached and penalties of up to $1 billion if the companies violate them.
Syphilis cases in babies skyrocket in Canada amid health-care failures
The numbers of babies born with syphilis in Canada are rising at a far faster rate than recorded in the United States or Europe, an increase public health experts said is driven by increased methamphetamine use and lack of access to the public health system for Indigenous people.
Oscar Pistorius denied parole as Reeva Steenkamp's parents oppose his early release
Disgraced South African Paralympic sprinter Oscar Pistorius has been denied parole, the lawyer for Reeva Steenkamp's parents said after the parole hearing.
House abandoned by couple who 'disappeared' years ago nightmare for neighbour on upscale street
A Toronto man, whose neighbours vanished eight years ago and left their home completely abandoned, said he's fed up living next door to a property that is in complete disarray.
Former Conservative leader Erin O'Toole not seeking re-election, leaving this spring
Former Conservative leader Erin O'Toole says he will not seek re-election and plans to resign his seat this spring. The Ontario MP led the Conservatives and served as official Opposition leader from August 2020 until February 2022, when a majority of his caucus voted to remove him from the post.
Trump's indictment in New York: Here's what to know
The vote of a Manhattan grand jury to indict the Republican former president on charges related to hush money payments made on his behalf during his 2016 presidential campaign catapults the now-candidate Donald Trump into a new era of legal risk and complicates his attempts to return to the White House.